Five common questions about CBD: answers for France

CBD (cannabidiol) is a cannabinoid produced naturally by the hemp plant (Cannabis sativa L.), mainly in the flowers and leaves, inside microscopic glands called trichomes. It is extracted through chemical processes (supercritical CO2, pharmaceutical ethanol), then diluted in a vegetable carrier oil.

CBD interacts with the endocannabinoid system, a network of receptors present in all mammals. Discovered in the 1990s, this system is involved in regulating several physiological functions (sleep, mood, appetite, pain, immunity). CBD has a weak affinity for the CB1 and CB2 cannabinoid receptors, and acts mainly through indirect modulation.

Important: the presence of a target system is not enough to demonstrate a clinical benefit. No French or European authority has validated a health claim for CBD.

No French authority recommends a standard dose. Practices observed in store range from 5 mg to 50 mg of CBD per intake, depending on the format and the use.

One useful benchmark: on 9 February 2026 the EFSA published a provisionally safe daily dose of 0.0275 mg/kg/day, that is around 2 mg/day for a 70 kg adult, calculated with an uncertainty factor of 400 on the basis of hepatotoxic effects observed in animals. That dose is far below common commercial dosages.

The general principles of cautious use:

• start with the minimum dose stated on the product label;
• take it at the same time each day for two weeks;
• adjust if necessary, increasing gradually;
• favour regularity over a single high dose.

For a sublingual oil, place the drops under the tongue and hold them there for 60 to 90 seconds before swallowing (better bioavailability).

Yes, under conditions. The French framework was stabilised by the ruling of the Conseil d'État of 29 December 2022 (no. 444887), which annulled the ban on selling hemp flowers and leaves.

The conditions to be met:

1. Variety taken from the official French catalogue or the common European catalogue;
2. Delta-9-THC content ≤ 0.30% in the finished product;
3. Absence of prohibited cannabinoids: HHC, H4CBD, H2CBD, HHCO, THCP, THCA, 10-OH-HHC, classified as narcotics by the ANSM in June 2024.

Note: since 15 May 2026, the DGAL has been applying the European Novel Food regulation strictly. CBD oils and food supplements without European authorisation are being withdrawn from the market. Cosmetic formats, vaporised flowers and "external-use wellness oils" remain authorised.

At common dosages and with controlled products, CBD is generally well tolerated. The documented adverse effects (drowsiness, dry mouth, mild digestive upset) are rarely serious.

But health alerts do exist. In 2024 the ANSES reported around twenty alerts passed on to French poison control centres for poisonings caused by CBD products contaminated with synthetic cannabinoids (HHC, THCP) or containing THC levels above 0.30%. In 2024, 17 "Rappels Conso" notices were published by the DGAL for non-compliant CBD products.

The practical consequence: always ask for the certificate of analysis (CoA) from an independent accredited laboratory (Cofrac, ISO 17025), dated to the batch purchased, showing:

• actual CBD content;
• delta-9-THC content < 0.30%;
• absence of prohibited cannabinoids;
• contaminants (heavy metals, pesticides, solvents) below the European Pharmacopoeia thresholds.

Driving risk. On 21 June 2023 the Cour de cassation confirmed that the commercial legality of a CBD product does not exonerate the driver in the event of a positive saliva test for THC. Traces of THC from a full spectrum can be enough. To drive without risk, favour an isolate certified THC-free.

Several profiles should be excluded or must seek a doctor's advice before any use:

• Pregnant or breastfeeding women. In June 2025 the ANSES proposed to the ECHA that CBD be classified as "presumed toxic to human reproduction" (category 1B). The precautionary principle applies.
• Women planning a pregnancy: the same caution during the preconception phase.
• Minors. No CBD wellness product should be offered to them. Only the medicine Epidyolex® (purified CBD on hospital prescription) is authorised in children for certain rare epilepsies.
• People on medication. CBD modulates the liver enzymes CYP3A4 and CYP2C9 and may interact with anticoagulants, antiepileptics, immunosuppressants, certain psychotropic drugs and antidepressants. Ask your doctor or pharmacist for advice.
• Professional drivers and athletes in competition. Favour an isolate or abstain, to avoid the risk of a positive THC test.
• People with liver disease: hepatotoxic effects documented in animals at high doses, caution recommended.

• CBD is produced by hemp, extracted and then diluted in a carrier oil.
• EFSA safe daily dose: 0.0275 mg/kg/day, that is ≈ 2 mg for 70 kg.
• Legal in France if the variety is authorised, finished-product THC ≤ 0.30%, and prohibited cannabinoids are absent.
• Always ask for a certificate of analysis from an independent laboratory.
• Not advised for: pregnant or breastfeeding women, minors, people on medication.
• CBD is not a medicine. If you have a medical concern, consult a healthcare professional.

Does CBD make you "high"?

No. Below 0.30% THC, a CBD product does not produce an intoxicating effect. Users report a sensation of relaxation, without any alteration of consciousness.

How long before an effect is felt?

It varies with the format. For a sublingual oil: 20 to 40 minutes. For a gummy or capsule: 60 to 90 minutes (digestive passage). For a vaporised flower: 5 to 15 minutes (shorter-lived effect). The perceived effect may require several days of regular use before it becomes noticeable.

Is CBD a drug?

No, in the French legal sense. CBD is not listed as a narcotic. It is a non-psychoactive compound from a plant that is authorised for cultivation.

Can it be taken every day?

No official framework specifies this. Observed practice includes daily use among roughly 84% of regular consumers in France (Visual CBD estimate). Note: the EFSA safe daily dose is very low (≈ 2 mg/day for 70 kg). It is advisable to reassess periodically whether the product is still of interest to you.

What should you do in the event of an adverse effect?

Stop taking it and consult a healthcare professional. You can also report the event to the poison control centre (national number) or to the ANSES (reporting portal). Keep the bottle and the batch number to make traceability easier.

To explore our selection of CBD oils, flowers and cosmetics with a certificate of analysis, [see our spectres-chimie catalogue](/categorie-produit/extracts-cbd). CBD is not a medicine. If you have a medical concern, consult a healthcare professional.

• French Public Health Code, art. L.5111-1 (definition of a medicine) — primary
• EFSA Journal 2026 — Update statement CBD novel food — primary
• ANSES — Press release 19 June 2025 on the classification of CBD as a reproductive toxicant (PDF) — primary